Sanofi's Sarclisa Goes Hands-Free: Will It Matter to Physicians?

Sanofi's Sarclisa Escena has been approved for subcutaneous administration using a hands-free on-body injector (CirCLIQ® OBI), making it the first anticancer treatment available via an automated wearable device in the US.
Clinical data from trials like IRAKLIA show non-inferior efficacy and safety compared with intravenous Sarclisa, with significantly shorter administration time and fewer systemic reactions (about 1.5% vs 25% with IV).
Both patients and healthcare professionals strongly prefer the hands-free option, with high completion rates and reports of reduced physical strain, easier patient monitoring, and improved workflow for nurses and physicians.
Physicians may find the hands-free option attractive because it reduces nursing burden, lowers the risk of infusion-related complications, and provides more flexibility in care settings, but adoption may depend on reimbursement policies, training, and clinic logistics.
For physicians, the main value lies in improved patient experience, operational efficiency, and potential to shift some care from infusion centers to more flexible outpatient or clinic-based settings, all without sacrificing clinical outcomes.